Loading
BLK (Tyrosine-protein kinase Blk) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Non-Hodgkin lymphoma and 2 more.
Non-receptor tyrosine kinase involved in B-lymphocyte development, differentiation and signalling. B-cell receptor (BCR) signalling requires a tight regulation of several protein tyrosine kinases and phosphatases, and associated coreceptors. Binding of antigen to the B-cell antigen receptor (BCR) triggers signalling that ultimately leads to B-cell activation.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Ibrutinib. Open Targets scores its association with cancer at 0.68 (direct and indirect evidence; datatypes literature 0.81, genetic association 0.48, clinical 0.96).
In plain words · BLK (Tyrosine-protein kinase Blk) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Non-Hodgkin lymphoma and 2 more.
BLK (Tyrosine-protein kinase Blk) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Non-Hodgkin lymphoma and 2 more.
Non-receptor tyrosine kinase involved in B-lymphocyte development, differentiation and signalling.
No product in this corpus aims at BLK yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA group enriched, which says where the protein sits but not whether the tumour differs from normal tissue. HPA BLK: RNA group enriched (intestine 40 nTPM, lymphoid tissue 50 nTPM); blood lineage lineage enriched (B-cells 168 nTPM); high antibody staining in 2 normal tissues. Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Leukaemia, Myeloid neoplasms, Lymphoma); Open Targets associates it with 2 specific cancer types at or above 0.5 (chronic myeloid leukemia, acute lymphoblastic leukemia). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas BLK tissue; Open Targets ENSG00000136573 associations
First described 1995. Earliest sequence paper UniProt cites for the protein: Islam K.B. et al, J. Immunol, 1995, "Molecular cloning, characterization, and chromosomal localization of a human lymphoid tyrosine kinase related to murine Blk". Source.
Sources: HGNC HGNC:1057 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P51451 (protein name, function text, keywords and locations (REST API)); CIViC gene BLK (1 evidence items, 0 assertions, 1 variants; diseases: B-cell Acute Lymphoblastic Leukaemia (GraphQL API, CC0)); Open Targets ENSG00000136573 (association with cancer (MONDO_0004992) 0.68; per-cancer scores at or above 0.5: acute lymphoblastic leukaemia 0.55, non-Hodgkin lymphoma 0.56, chronic myelogenous leukaemia, BCR-ABL1 positive 0.60, myeloproliferative neoplasm 0.60, leukaemia 0.61 (GraphQL API, CC0))
Non-receptor tyrosine kinase involved in B-lymphocyte development, differentiation and signalling. B-cell receptor (BCR) signalling requires a tight regulation of several protein tyrosine kinases and phosphatases, and associated coreceptors. Binding of antigen to the B-cell antigen receptor (BCR) triggers signalling that ultimately leads to B-cell activation. Signalling through BLK plays an important role in transmitting signals through surface immunoglobulins and supports the pro-B to pre-B transition, as well as the signalling for growth arrest and apoptosis downstream of B-cell receptor. Specifically binds and phosphorylates CD79A at 'Tyr-188'and 'Tyr-199', as well as CD79B at 'Tyr-196' and 'Tyr-207'. Also phosphorylates the immunoglobulin G receptors FCGR2A, FCGR2B and FCGR2C. Location: Cell membrane (UniProt). Locus 8p23.1 (HGNC).
RNA: group enriched (intestine 40 nTPM, lymphoid tissue 50 nTPM), detected in some normal tissues. Blood: lineage enriched (B-cells 168 nTPM).
Medium: Appendix, Lung, Lymph node, Tonsil.
No cancer stained high; medium in breast cancer, carcinoid, colorectal cancer, endometrial cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"BLK" OR ABSTRACT:"BLK" OR TITLE:"BLK proto-oncogene, Src family tyrosine kinase" OR ABSTRACT:"BLK proto-oncogene, Src family tyrosine kinase" OR TITLE:"Tyrosine-protein kinase Blk" OR ABSTRACT:"Tyrosine-protein kinase Blk" OR TITLE:"MGC10442" OR ABSTRACT:"MGC10442") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BLK, not a curated reading list.
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types).
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, CIViC, Non-Hodgkin lymphoma (all types).
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types), Open Targets Platform.